Progressive supranuclear palsy presenting with corticobasal syndrome: a case report
Objective: Clinical description and interpretation of complementary diagnostic exams of a patient with probable PSP with corticobasal syndrome phenotype (PSP-CBS). Background: Underlying pathologies of CBS…To Study the Role of Biomarkers DJ-1 and Apo A1 in Idiopathic Parkinson’s Disease and Parkinson Plus Syndromes in Indian Population
Objective: To study the role of serum DJ-1 and Apo A1 in the diagnosis and differentiation of Idiopathic Parkinson Disease (IPD) and Parkinson Plus Syndromes(PPS)…Movement Disorder Society – Clinical Diagnostic Criteria for Progressive Supranuclear Palsy
Objective: The International Parkinson and Movement Disorders Society-endorsed PSP Study Group aimed to provide an evidence- and consensus-based revision of the clinical diagnostic criteria for…Aspects of Quality of Life in MSA and PSP
Objective: The aim of this study was exploring the correlation between disease severity and QoL in PSP and MSA. Background: MSA and PSP are atypical Parkinsonian disorders that…Can the level of CSF Neurofilament Light Chain predict disease progression in Progressive Supranuclear Palsy?
Objective: To investigate whether the level of CSF Neurofilament Light Chain (NFL) can predict the speed of disease progression in patients with Progressive Supranuclear Palsy…Results of a Phase 1, Single Ascending Dose, Placebo-Controlled Study of ABBV-8E12 in Patients with Progressive Supranuclear Palsy and Phase 2 Study Design
Objective: To present the results of a phase 1 study of ABBV-8E12 in subjects with Progressive Supranuclear Palsy (PSP) and design of a phase 2…Reversible progressive supranuclear palsy-mimic induced by risperidone
Objective: To report a patient who presented with a progressive supranuclear palsy (PSP)-like syndrome while receiving risperidone that disappeared after drug withdrawal. Background: Drugs that…Diagnostic utility of regional [18F]AV-1451 tau-PET measurements in PSP
Objective: To determine the diagnostic utility of regional subcortical [18F]AV-1451 tau-PET measurements to differentiate progressive supranuclear palsy (PSP) from age-matched controls and Alzheimer’s dementia patients.…Differential diagnosis of Parkinson’s Disease and Progressive Supranuclear Palsy
Objective: The description of differential diagnostic features of PSP and PD in order to improve the diagnosis and the differential diagnosis of these diseases. Background:…Are a „mathematical brain“ and early childhood adverse events possible risk factors that contribute to Progressive Supranuclear Palsy?
Objective: To evaluate possible risk factors for the development of Progressive Supranuclear Palsy (PSP). Background: Risk factors for the development of neurodegenerative brain disorders are…
- « Previous Page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- …
- 42
- Next Page »